American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate.
作者信息
Senchyna A, Simon S, Cissé H, Ginouves M, Prevot G, Alcoba G, Demar M, Couppie P, Blaizot R
机构信息
Dermatology Department, Andrée Rosemon Hospital, Cayenne, French Guiana.
EA 3593 Ecosystèmes Amazoniens et Pathologies Tropicales, University of French Guiana, Cayenne, French Guiana.
出版信息
Br J Dermatol. 2020 Aug;183(2):389-391. doi: 10.1111/bjd.18964. Epub 2020 Mar 31.
Abstract
摘要
相似文献
1
American cutaneous leishmaniasis in French Guiana: a retrospective comparison between liposomal amphotericin B and meglumine antimoniate.法属圭亚那的美洲皮肤利什曼病：两性霉素B脂质体与葡甲胺锑酸盐的回顾性比较
Br J Dermatol. 2020 Aug;183(2):389-391. doi: 10.1111/bjd.18964. Epub 2020 Mar 31.
2
Effective meglumine antimoniate intralesional therapy for Chiclero's ulcer refractory to systemic liposomal amphotericin B.有效的葡甲胺锑酸盐病灶内治疗对全身应用脂质体两性霉素B难治的希克勒罗溃疡。
J Travel Med. 2021 Aug 27;28(6). doi: 10.1093/jtm/taaa169.
3
Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a -endemic area.葡甲胺锑酸钠治疗皮肤利什曼病的治愈率高于脂质体两性霉素 B：来自流行地区的回顾性队列研究。
Front Cell Infect Microbiol. 2022 Sep 23;12:993338. doi: 10.3389/fcimb.2022.993338. eCollection 2022.
4
Pilot study of safety and efficacy of topical liposomal amphotericin B for cutaneous leishmaniasis caused by Leishmania major in Islamic Republic of Iran.伊朗伊斯兰共和国局部应用脂质体两性霉素B治疗硕大利什曼原虫引起的皮肤利什曼病的安全性和有效性的初步研究。
East Mediterr Health J. 2022 Sep 29;28(9):658-663. doi: 10.26719/emhj.22.070.
5
The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.含硬脂胺脂质体包裹的葡甲胺锑酸盐对BALB/c小鼠皮肤利什曼病的活性
Exp Parasitol. 2019 May;200:30-35. doi: 10.1016/j.exppara.2019.03.004. Epub 2019 Mar 18.
6
Comparison of Resistance of Wild İsolates, Which are Resistant to Pentavalent Antimonial Compounds, Against Drugs Used in the Treatment of Leishmaniasis.对五价锑化合物耐药的野生分离株对用于治疗利什曼病的药物的耐药性比较。
Turkiye Parazitol Derg. 2020 Mar 20;44(1):12-16. doi: 10.4274/tpd.galenos.2019.6661.
7
Cutaneous leishmaniasis in French Guiana: a review.法属圭亚那的皮肤利什曼病：综述
Am J Trop Med Hyg. 1990 Jul;43(1):25-8. doi: 10.4269/ajtmh.1990.43.25.
8
A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis.一项比较葡甲胺锑酸盐、喷他脒和两性霉素B治疗圭亚那利什曼原虫引起的皮肤利什曼病的随机临床试验。
An Bras Dermatol. 2011 Nov-Dec;86(6):1092-101. doi: 10.1590/s0365-05962011000600005.
9
American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.美国皮肤利什曼病由对抗锑剂葡萄糖酸锑钠耐药但对喷他脒敏感的巴西利什曼原虫引起：病例报告。
Rev Soc Bras Med Trop. 2011 Mar-Apr;44(2):254-6. doi: 10.1590/s0037-86822011000200026.
10
Localized leishmaniasis treated with intralesional meglumine antimoniate.局部注射葡甲胺锑酸盐治疗局部利什曼病。
J Dtsch Dermatol Ges. 2020 Sep;18(9):1025-1027. doi: 10.1111/ddg.14165. Epub 2020 Jul 12.
引用本文的文献
1
[Overview of infectious and non-infectious diseases in French Guiana in 2022].[2022年法属圭亚那传染病和非传染病概述]
Med Trop Sante Int. 2023 Feb 17;3(1). doi: 10.48327/mtsi.v3i1.2023.308. eCollection 2023 Mar 31.
2
Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations.脂质体两性霉素B治疗利什曼病：从关键物理化学特性的鉴定到有效局部和口服制剂的设计
Pharmaceutics. 2022 Dec 28;15(1):99. doi: 10.3390/pharmaceutics15010099.
3
Meglumine antimoniate was associated with a higher cure rate than liposomal amphotericin B in the treatment of American tegumentary leishmaniasis: A retrospective cohort study from a -endemic area.葡甲胺锑酸钠治疗皮肤利什曼病的治愈率高于脂质体两性霉素 B：来自流行地区的回顾性队列研究。
Front Cell Infect Microbiol. 2022 Sep 23;12:993338. doi: 10.3389/fcimb.2022.993338. eCollection 2022.
4
Cutaneous leishmaniasis in travellers and migrants: a 10-year case series in a Canadian reference centre for tropical diseases.旅行者和移民中的皮肤利什曼病：加拿大热带病参考中心的 10 年病例系列。
CMAJ Open. 2022 Jun 21;10(2):E546-E553. doi: 10.9778/cmajo.20210238. Print 2022 Apr-Jun.
5
Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes.两性霉素B聚乙二醇化脂质体的制剂，用于通过肠胃外和口服途径改善皮肤利什曼病的治疗。
Pharmaceutics. 2022 May 5;14(5):989. doi: 10.3390/pharmaceutics14050989.
6
Outbreak of Cutaneous Leishmaniasis among military personnel in French Guiana, 2020: Clinical, phylogenetic, individual and environmental aspects.2020 年法属圭亚那军人中皮肤利什曼病的爆发：临床、系统发育、个体和环境方面。
PLoS Negl Trop Dis. 2021 Nov 19;15(11):e0009938. doi: 10.1371/journal.pntd.0009938. eCollection 2021 Nov.
7
Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B.脂质体两性霉素B治疗复杂性皮肤利什曼病
Pathogens. 2021 Sep 28;10(10):1253. doi: 10.3390/pathogens10101253.
8
Intravenous liposomal amphotericin B efficacy and safety for cutaneous and mucosal leishmaniasis: a systematic review and meta-analysis protocol.静脉注射脂质体两性霉素 B 治疗皮肤和黏膜利什曼病的疗效和安全性：系统评价和荟萃分析方案。
BMJ Open. 2021 Jun 16;11(6):e045707. doi: 10.1136/bmjopen-2020-045707.
9
Validation of Swab Sampling and SYBR Green-Based Real-Time PCR for the Diagnosis of Cutaneous Leishmaniasis in French Guiana.拭子采样和 SYBR Green 实时 PCR 对法属圭亚那皮肤利什曼病诊断的验证。
J Clin Microbiol. 2021 Jan 21;59(2). doi: 10.1128/JCM.02218-20.
本文引用的文献
1
American cutaneous leishmaniasis in French Guiana: an epidemiological update and study of environmental risk factors.法属圭亚那的美国皮肤利什曼病：流行病学最新情况和环境危险因素研究。
Int J Dermatol. 2019 Nov;58(11):1323-1328. doi: 10.1111/ijd.14625. Epub 2019 Sep 16.
2
Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.脂质体两性霉素B治疗皮肤和黏膜皮肤利什曼病旅行者：并非万灵药。
PLoS Negl Trop Dis. 2017 Nov 20;11(11):e0006094. doi: 10.1371/journal.pntd.0006094. eCollection 2017 Nov.
3
Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).利什曼病的诊断和治疗：美国传染病学会 (IDSA) 和美国热带医学与卫生学会 (ASTMH) 的临床实践指南。
Clin Infect Dis. 2016 Dec 15;63(12):e202-e264. doi: 10.1093/cid/ciw670. Epub 2016 Nov 14.
4
Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.脂质体两性霉素B（安必素（®））：药代动力学、药效学、临床经验及未来方向综述
Drugs. 2016 Mar;76(4):485-500. doi: 10.1007/s40265-016-0538-7.
5
Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers.脂质体两性霉素 B 与葡萄糖酸锑钠治疗旅行者巴西利什曼原虫皮肤利什曼病的比较。
J Am Acad Dermatol. 2013 Feb;68(2):284-9. doi: 10.1016/j.jaad.2012.06.014. Epub 2012 Aug 1.
6
Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis?我们能否使用更低剂量的脂质体两性霉素 B 来治疗黏膜型皮肤利什曼病？
Am J Trop Med Hyg. 2011 Nov;85(5):818-9. doi: 10.4269/ajtmh.2011.11-0287.
7
Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis.脂质体两性霉素 B 治疗皮肤利什曼病。
Am J Trop Med Hyg. 2010 Nov;83(5):1028-33. doi: 10.4269/ajtmh.2010.10-0171.
8
Practical guide for the treatment of leishmaniasis.利什曼病治疗实用指南。
Drugs. 1998 Dec;56(6):1009-18. doi: 10.2165/00003495-199856060-00005.
Zotero 插件